Primary and secondary immune thrombocytopenia (ITP): Time for a rethink
- PMID: 37414719
- DOI: 10.1016/j.blre.2023.101112
Primary and secondary immune thrombocytopenia (ITP): Time for a rethink
Abstract
There are not many publications that provide a holistic view of the management of primary and secondary ITP as a whole, reflecting the similarities and differences between the two. Given the lack of major clinical trials, we believe that comprehensive reviews are much needed to guide the diagnosis and treatment of ITP today. Therefore, our review addresses the contemporary diagnosis and treatment of ITP in adult patients. With respect to primary ITP we especially focus on establishing the management of ITP based on the different and successive lines of treatment. Life-threatening situations, "bridge therapy" to surgery or invasive procedures and refractory ITP are also comprehensively reviewed here. Secondary ITP is studied according to its pathogenesis by establishing three major differential groups: Immune Thrombocytopenia due to Central Defects, Immune Thrombocytopenia due to Blocked Differentiation and Immune Thrombocytopenia due to Defective Peripheral Immune Response. Here we provide an up-to-date snapshot of the current diagnosis and treatment of ITP, including a special interest in addressing rare causes of this disease in our daily clinical practice. The target population of this review is adult patients only and the target audience is medical professionals.
Keywords: Diagnosis; Primary immune thrombocytopenia (ITP); Refractory ITP; Secondary immune thrombocytopenia; Thrombopoietin receptor agonists (TPO-RAs); Treatment.
Copyright © 2023 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest Tomás José González-López has received research grants from Amgen and Novartis and speaker honoraria from Amgen, Novartis, Sobi, Grifols and Argenx. Drew Provan has received research support and honoraria from Amgen and Novartis and has acted as a consultant for UCB, MedImmune, Ono and Takeda. Dr. Jarque-Ramos reports consulting honorarium from Amgen, Novartis and Shionogi. Rest of authors declare no competing financial interests.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources